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Evaluationofalargernumberofchemicalsincommercefromtheperspectiveofpotentialhumanhealthriskhasbecomeafocusof
attention in North America and Europe. Screening-level chemical risk assessment evaluations consider both exposure and hazard.
Exposures are increasingly being evaluated through biomonitoring studies in humans. Interpreting human biomonitoring results
requires comparison to toxicity guidance values. However, conventional chemical-speciﬁc risk assessments result in identiﬁcation
of toxicity-based exposure guidance values such as tolerable daily intakes (TDIs) as applied doses that cannot directly be used
to evaluate exposure information provided by biomonitoring data in a health risk context. This paper describes a variety of
approaches for development of screening-level exposure guidance values with translation from an external dose to a biomarker
concentration framework for interpreting biomonitoring data in a risk context. Applications of tools and concepts including
biomonitoring equivalents (BEs), the threshold of toxicologic concern (TTC), and generic toxicokinetic and physiologically based
toxicokinetic models are described. These approaches employ varying levels of existing chemical-speciﬁc data, chemical class-
speciﬁc assessments, and generic modeling tools in response to varying levels of available data in order to allow assessment and
prioritization of chemical exposures for reﬁned assessment in a risk management context.
1.Introduction
Recognition of the large numbers of chemicals in commerce
and increased focus on evaluation of these chemicals from
the perspective of potential human health risk has become
a focus of attention in North America and Europe. These
eﬀorts are devoted not only to evaluation of “new” chemicals
but also to an examination of existing chemical substances.
These eﬀorts include those under the Health Canada Chem-
icals Management Plan, the European Registration, Evalua-
tion, Authorisation and Restriction of Chemicals (REACh),
the High Production Volume (HPV) Challenge Program,
and the US Environmental Protection Agency’s (US EPA)
Chemical Assessment and Management Program (ChAMP)
initiatives. Chemical evaluation is also being discussed as
part of potential improvements to the US Toxic Substances
Control Act. Because of the large number of chemicals
involved andtheneedforeﬃcientprocessesthatassurefocus
on substances which could pose the greatest health concerns,
tiered approaches that begin with conservative risk-based
screening-level assumptions and proceed to more reﬁned
data-intensive approaches have been recommended for these
types of eﬀorts [1, 2].
Chemical risk assessment evaluations consider both ex-
posure and hazard, and a tiered set of approaches employing
various levels of data for screening-level assessments is often
recommended [1, 3, 4]. Exposure screening considers chem-
ical uses, identiﬁes potential exposure media or pathways,
and invokes conservative assumptions in the estimation of
potential daily exposure rates. Hazard evaluation includes
the identiﬁcation of established tolerable exposure levels
(e.g., reference doses or tolerable daily intakes [RfDs or2 Journal of Toxicology
TDIs]). In the absence of such established guidance values,
robust no observed adverse eﬀect levels (NOAELs) or bench-
mark doses (BMDs) can be used as a point of departure
(POD) and adjustment factors for extrapolation applied
(as necessary), and margins of safety (MOS) can then be
calculated for risk-based screening. Finally, in the absence
of robust toxicological data, a generic screening approach
such as that developed under the threshold of toxicological
concern (TTC) framework [5–7] for setting conservative
tolerable intake rates has been widely used.
In this paper, we explore approaches for using chemical
biomonitoring data in risk assessment evaluation of chemi-
cals. As with external exposure-based assessments, exposure
assessments based on biomonitoring data require health-
or risk-based benchmarks for evaluation of biomarker data.
However, because biomarker data is typically expressed in
units of biomarker concentration (e.g., µg/L urine) and risk-
based benchmarks are typically expressed in units of applied
dose (mg/kg-day), direct comparison cannot be made. Two
approaches are possible: (1) the biomarker can be back
calculated to an applied dose (reverse dosimetry; see, e.g.,
[8]), or (2) the benchmark can be forward calculated
to a corresponding biomarker concentration for use as a
screening value (forward dosimetry; see Hays et al. [9]).
Dosimetry calculations, whether forward or reverse,
require the use of pharmacokinetic data and modeling
and assumptions regarding exposure patterns. This paper
describes methods for interpreting human biomonitoring
data in a risk context, illustrating the use of the forward
dosimetry biomonitoring equivalents approach for ﬁve sce-
narios. The ﬁrst three are applicable to substances for which
toxicokinetics are well understood but that have diﬀerent
levels of toxicity data: (1) substances with established gov-
ernment risk assessments, (2) substances with suﬃcient
toxicity datasets but as of yet no government-generated (or
-vetted) risk assessment, and (3) substances amenable to
the generic screening TTC approach for setting conservative
tolerableintakerates.Theselattertwoapproachesareneeded
because,formanychemicalsincommonusetoday,theremay
not be authoritative, government-conducted, or “approved”
chemical-speciﬁc risk assessment-based exposure guidance
values available. The additional scenarios addressed in
this paper include (4) the absence of chemical-speciﬁc
toxicokinetic data or models, and (5) the absence of both
toxicity-based guidance values and toxicokinetic data. The
framework of the cases and approaches described here is
summarized in Figure 1 and discussed in detail below.
2. Using Risk Assessment Methods to Interpret
Human Biomonitoring Results
Human biomonitoring, in which chemicals or their metabo-
lites,aremeasuredinbiologicalmediasuchasbloodorurine,
has become a powerful tool in the assessment of chemical
exposuresinthegeneralpopulationandinstudiesoftargeted
populations [10, 11]. Human biomonitoring data provide
a reﬂection of integrated exposure from multiple pathways
and routes in terms of internal, biologically relevant dose. In
situations in which exposures to a chemical potentially occur
through multiple or ill-deﬁned exposure routes or pathways,
well-designed and conducted human biomonitoring studies
can provide robust and reliable exposure data that can com-
plement and reﬁne or replace external exposure estimation
basedonmoreindirectapproachesandgenericassumptions.
Biomonitoring can be particularly useful in cases where
widespread population exposure is possible (e.g., residues
of agricultural chemicals, food packaging constituents, con-
sumer product ingredients, etc.). Biomonitoring can also
be used as an accessory tool in evaluation of exposure
to chemical ingredients in consumer products in targeted,
controlled exposure studies (see below for example with
triclosan).
2.1. Biomonitoring Equivalents Based on Substances with
Established Government Risk Assessments and Established
Toxicokinetics. Screening criteria for determining the health
signiﬁcance of human biomonitoring results would ideally
be based on robust datasets relating potential adverse eﬀects
to biomarker concentrations in human populations (see,
e.g., the US Centers for Disease Control and Preven-
tion (CDC) blood lead level of concern; see http://www
.cdc.gov/nceh/lead/). However, data to support such assess-
ments exist for only a few environmental chemicals because
this approach requires establishment of causality in epidemi-
ological studies and a robust understanding of human dose
response. Thus, in an alternative approach, the concept of
biomonitoring equivalents (BEs) has been developed, and
guidelines for the derivation and communication of these
values have been published [9, 12, 13].
In conventional risk assessment, concentrations in envi-
ronmental media are used with speciﬁc contact scenarios to
derive an estimate of external dose (mg/kg-day), and this is
then compared to an external dose health-based guidance
value, such as an ADI, RfD or TDI (mg/kg-day). In the
initial screening-level evaluation, estimated exposure rates
are compared to hazard- or risk-based benchmarks to assess
whether more reﬁned evaluations are required. When an
RfD, or TDI or analogous screening value such as a TTC is
available, the screening-level exposure estimate is compared
directly to that value to assess whether exposure rates above
that value are anticipated. If a NOAEL or other POD
is used as the benchmark, then adjustment factors (AFs)
(synonymous with uncertainty factors or safety factors) are
generally used to extrapolate from animal toxicity to humans
(default 10x) and to account for human variability (default
10x). Depending upon the database and quality of studies,
additional AFs may be used [14]. If a toxicity database is
not robust, use of an additional database uncertainty factor
should be considered. Once the screening level health-based
exposureguidancevaluehasbeendetermined,thenamargin
of safety (MOS) can be calculated by comparing this to the
estimated daily dose rate (D):
MOS =
(POD/AFs)
D
. (1)
MOS values below 1 indicate that exposures exceed the
screening level health-based exposure guidance value. IfJournal of Toxicology 3
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Figure 1: Flowchart showing approaches for development of screening values for assessment of biomonitoring data for chemicals with
varying levels of available data on both hazard and toxicokinetics.
screening approaches have been used in the exposure or haz-
ard assessment process, further reﬁnement in those assess-
ments may be warranted. Such reﬁnements to provide
greater certainty of potential hazards and exposures may
include generation of product-speciﬁc exposure data for
chemicaluseswithhigherestimatedexposurerates,conduct-
ing speciﬁc toxicity studies to address database deﬁciencies,
or other exposure or hazard characterization reﬁnements.
Results of reﬁned assessments can be used to identify the
need for, and useful focus of, potential risk management
strategies.
In the biomonitoring equivalent approach for interpret-
ing biomonitoring exposure data (internal dose concentra-
tions) in a risk assessment context, external dose health-
based guidance values are translated to estimates of corre-
sponding steady-state biomarker concentrations. A biomon-
itoring equivalent (BE) is deﬁned as the concentration or
range of concentrations of a chemical or its metabolites in
a biological medium (blood, urine, or other medium) that is
consistent with an existing health-based exposure guidance
value such as a reference dose (RfD) or tolerable or accept-
able daily intake (TDI or ADI) [12]. BEs are intended to be
used as screening tools to provide an assessment of which
chemical biomarkers are present at levels well below, near, or
at or above concentrations that are consistent with existing
risk assessments and exposure guidance values, and thus can
provide an evaluation of relative priority for risk assessment
followup. BEs provide a translational tool allowing appli-
cation of the foundational risk assessment paradigm to the
evaluationofexposureinformationprovidedbybiomonitor-
ing data. Development of BE values requires an underlying
exposure guidance value (such as an RfD or TDI) as well
as suﬃcient understanding of pharmacokinetics of the
chemicalinhumansorkeylaboratoryspecies.BEsaresimilar
in concept to the HBM-I assessment values derived by the
Germanhumanbiomonitoringcouncil(reviewedinAngerer
et al. [15]). For interpreting human biomonitoring data in a
risk context, the margin of safety (MOS) approach is used
MOS =
BE
[Biomarker]
. (2)
When the MOS value is 1 or greater, then the exposure to
the substance is not likely to be of concern.
BE values have been derived for approximately 80 chemi-
cals in a variety of chemical classes (see Angerer et al. [15]f o r
review). BE derivations have been published for persistent
organic compounds including dioxins, hexachlorobenzene,
and DDT and metabolites, for approximately 40 volatile
organic compounds, for several phthalates and phenols
including di-2(ethylhexyl)phthalate, bisphenol A, and tri-
closan, for selected pyrethroid pesticides, and for selected
brominated ﬂame retardant compounds. For many of these
chemicals,multiple BEvalueshavebeenderivedcorrespond-
ing to diﬀerent available risk assessment exposure guidance
value (e.g., EPA RfDs versus TDI values derived by the Euro-
pean Food Safety Authority [EFSA]). For these chemicals,
screening level assessments of population biomonitoring
data can be made by comparison of the data to the BE value4 Journal of Toxicology
corresponding to the risk assessment exposure guidance
value deemed most appropriate.
2.2. Risk-Based Interpretation of Biomonitoring Based on Sub-
stances with Suﬃcient Toxicity Datasets but No Government-
Generated (or Approved) Risk Assessment. Establishing com-
prehensive, risk assessment-based exposure guidance values
such as RfDs or TDIs is a resource-intensive eﬀort that may
take several years to complete for substances with extensive
datasets. In many cases, substantial toxicological data exist
for chemicals, but no formal risk assessment-based exposure
guidance values such as an RfD or TDI have yet been estab-
lished by a government agency. Further, some existing risk-
assessment based values may now be outdated, based on the
availability of newer, more relevant hazard or exposure data.
Thus, for many chemicals in common use today, there may
not be authoritative, government-conducted or -approved
chemical-speciﬁc risk assessment-based exposure guidance
values available. In the absence of such established guidance
values,robustnoobservedadverseeﬀectlevelsorbenchmark
doses based on a review of available datasets can be used
as a point of departure, and by use of appropriate AFs,
screening level health-based exposure guidance values can be
derived. If appropriate pharmacokinetic data are available,
these screening level health-based exposure guidance values
can be translated to corresponding internal biomarker
concentrationsandusedtoassesshumanbiomonitoringdata
in a parallel fashion. A MOS based on comparison of the
biomonitoring data to the biomarker concentration level
consistent with the screening level health-based exposure
guidance value can then be calculated.
An example of this approach has been presented by
Aylward and Hays [16] for the ﬂame retardant hexabro-
mocyclododecane (HBCD). Although a substantial database
of toxicity data for both standard and endocrine-sensitive
endpoints is available, no exposure guidance values have
been established. Both Health Canada and the European
Union have conducted provisional or draft risk assessments
in which sensitive PODs were identiﬁed [17, 18]. Data were
available on measured or estimated lipid-adjusted HBCD
concentrations in experimental animals at the identiﬁed
POD dose levels. Substantial data on lipid-adjusted HBCD
concentrations in human serum and milk were available
and tabulated. Comparison of those data to the biomarker
concentrations in the animal studies at the PODs showed
margins of exposure (MOEs) in excess of 5,000 for general
population exposures to HBCD [16]. In this case, a MOE
comparison was made, which is analogous to the MOS
approach, except with the MOE, AFs are not used, and
comparison is made directly to the POD.
A similar MOE approach was incorporated as part of
a risk assessment for triclosan conducted by the European
Commission Scientiﬁc Committee on Consumer Products
(ECSCCP) [19]. In this case, serum concentrations of
triclosan were measured throughout the course of a chronic
animal bioassay selected by the ECSCCP as the basis for
establishment of a TDI. Thus, serum concentrations in rats
corresponding to the NOAEL dosing regimen were directly
available from the toxicological database. In contrast to
HBCD, in which general population exposures are incidental
and due to trace levels of HBCD released into the envi-
ronment, triclosan is added intentionally as an antibacterial
agent to a variety of directly applied and used personal
care products such as toothpaste or soap. Thus, direct
consumer exposure is anticipated. The conventional risk
assessment approach entails estimation of exposure levels
using generic assumptions about each use scenario, contact
rates, absorption, and so forth. However, because consumers
may experience exposures to multiple products containing
triclosan, with potential exposure via more than one route
(dermal, ingestion), the conventional exposure assessment
process can be cumbersome, requiring assessment of many
exposure scenarios and reliance on multiple conservative,
potentially compounding, exposure assumptions.
In the ECSCCP evaluation, in addition to a conventional
MOE assessment based on estimated external doses from
use of multiple products compared to an animal NOAEL, a
biomarker-basedassessmentwasalsoconducted.Peakserum
levels were measured in volunteers using multiple triclosan-
containing products (toothpaste, deodorant stick, and hand
soap) and compared to the serum levels at the NOAEL in
rats in the chronic bioassay. The conventional assessment
based on estimated external doses resulted in an MOE
of approximately 380 compared to the administered dose
rates in rats at the NOAEL. The corresponding assessment
based on comparison of human serum levels to serum levels
measured in the animal bioassay at the NOAEL resulted
in an MOE of approximately 940. This result conﬁrms (1)
that the approach based on estimated external exposures
incorporates conservative assumptions and (2) the practical
utility of risk-based screening using biomonitoring data.
The triclosan example illustrates the value of including
measurements of blood biomarker concentrations in toxi-
cological assays, as recommended by Barton et al. [20]a n d
Saghir et al. [21]. Biomarker concentrations, and in partic-
ular blood or serum concentrations of chemicals, provide a
reﬂection of biologically relevant absorbed dose and tissue
concentrations. Comparison of biomarker concentrations
in humans under real-world product use scenarios to
the corresponding biomarker concentrations in laboratory
animals under bioassay conditions at the POD potentially
reduces uncertainties associated with reliance on estimated
external exposure doses in the process of safety assessment of
products.
Interpreting human biomonitoring data in a risk context
for substances that lack comprehensive, health-based expo-
sure guidance values is challenging.
Programs such as Health Canada’s Chemicals Manage-
ment Plan, the European Union (EU) Registration, Evalua-
tion, Authorisation, and Restriction of Chemical (REACh),
and the US Toxic Substances Control Act (HPV Challenge
Program and ChAMP), while they may be lacking health-
based exposure guidance values, can often provide suﬃcient
data to support this screening-level approach.
For example, under the High Production Volume
(HPV) Challenge Program (http://www.epa.gov/chemrtk/
index.htm) which is now substantially complete, toxicityJournal of Toxicology 5
data and other relevant information on approximately 2,200
chemicals produced or imported into the US, in quantities
>1,000,000lbs./year, has been submitted to EPA to enable
screening based on the OECD’s SIDS paradigm. This data,
which covers about 90–95% by volume of chemicals in
commerce in the US, is publicly available and was evaluated
by EPA, under the Chemical Assessment and Management
Program (ChAMP) initiative, to derive screening-level haz-
ard characterizations, and then, for a subset of these, a
screening-level risk-based prioritization. From its initiation
in 2007 to 2009, when it was superseded, EPA’s ChAMP
developed 786 hazard characterizations and 220 risk-based
prioritizations [22, 23].
Foreachofthesesubstances,thehazardcharacterizations
generatedbyEPAprovideaconciseassessmentofthetoxicity
data and include delineation of LOAELs and NOAELs for
eﬀects on (1) major organ systems (from both acute and
repeated exposures), (2) the developing organism in utero,
(3) reproduction, and (4) the ﬁdelity of DNA (http://www
.epa.gov/champ/). The LOAELS or NOAELs (as appropriate)
for these substances can be readily accessed from EPA’s
HPVIS online database (http://www.epa.gov/hpv/hpvis/
index.html) and used for deriving a POD. These values are
typically expressed as applied doses in mg/kg-day. AFs for
toxicodynamics can then be applied to derive a screening
level health-based exposure guidance value, which is also
in units of applied dose (mg/kg-bw/day). Then, by using
chemical-speciﬁc toxicokinetic data or models (CSTK), a
biomarker concentration level typically in units of con-
centration in blood or urine consistent with this screen-
ing level health-based exposure guidance values can be de-
veloped. Biomonitoring results can then be interpreted in a
risk context using the MOS procedure.
When using this approach, it is important to recognize
that the typical AFs of 10x for extrapolating to animals
to humans and 10x to account for human variability each
contain both dynamic and kinetic components [24]. Thus,
to use this method to interpret human biomonitoring data,
when deriving the screening level health-based exposure
guidance value from a NOAEL or POD based on an oral
toxicity lab animal study, it is important to use in the ﬁrst
step only the dynamic components of the AFs (typically 2.5x
or 3.16x to extrapolate from animals to humans and 3.16x
to account for human variability) should be used [24, 25].
Then, in a second step, the CSTK data or model needs to
be used to convert the applied dose into a concentration
and in doing so, the CSTK may allow replacement of the
kinetic components of the typical AFs. If both the typical
10x for extrapolating from animals to humans and the 10x to
account for human variability are applied to the lab animal
toxicity NOAEL and the CSTK is also applied, “double
counting” for toxicokinetics would occur.
2.3. Risk-Based Interpretation of Biomonitoring Based on the
Thresholds of Toxicological Concern (TTC) Method. In some
cases, no robust toxicological data on which to base selection
of a POD are available for a chemical. In this case, the TTC
approachcanprovideamethodforselectionofaprovisional,
conservative tolerable daily dose level based on historical
data and distributions of NOAEL values (or cancer potency
values) along with an appropriate uncertainty factor (or
low dose linear extrapolation factor) for a wide range of
compounds [5–7, 26, 27]. The threshold of toxicological
concern (TTC) evolved from concepts initially developed
by Frawley [28] and further reﬁned by the US FDA as
the threshold of regulation [29, 30] and was initially
developed based on extrapolated risk data for carcinogens
with the assumption that if the carcinogenicity endpoint
was protected, all other toxicological endpoints would also
b ep r o t e c t e d .T h e s ec o n c e p t sw e r ec o n s i d e r a b l ye x p a n d e dt o
include consideration of chemical structure in conjunction
with toxicity data for other toxicological endpoints [5, 27].
One of the most important enhancements to the original
work was the consideration of chemical structure and the
addition of a decision tree linked to exposures that pose little
ornohealthrisk.Theacceptableexposurelevelswerederived
by an extensive analysis of the existing toxicology data for
730chemicalstestedforcarcinogenicity(lowdoseriskbased)
and more than 600 chemicals tested for repeat dose toxicity
(NOAEL based) [31].
The TTC approach provides a decision tree linking
chemical structure with toxicity. Chemical characteristics are
used to identify a generic, conservative tolerable daily intake
rate, the TTC. The TTC approach is based on an analysis
of two comprehensive databases of toxicity data: one that is
relevant to genotoxic carcinogens and one that is relevant
to repeat dose endpoints not predicted on an assumption
of potential genotoxic carcinogenicity. These tools are used
by ﬁrst assessing conservatively whether or not the chemical
has structural features (alerts) suggestive of the potential for
carcinogenicity via a genotoxic mode of action. Chemicals
with alerts for potential genotoxic carcinogenicity are subject
to an exposure limit based on the distribution of potencies of
historically tested carcinogens. Chemicals without alerts for
genotoxicity may move further along the decision tree, and,
based on their structures, be categorized into one of three
classes that are associated with three diﬀerent conservative
tolerable intake rates, or TTCs [27]. The category-speciﬁc
recommended TTC levels are considered to be conservative
estimates of chronic daily intake rates that are unlikely to
result in adverse eﬀects. This is based on the analysis of the
distribution of no observed adverse eﬀect levels (NOAELS)
forcompoundsinthethreecategories.Thesevaluesarebased
on the 5th percentile NOAELS along with the application
of default uncertainty factors [5–7]. Applying the TTC
approach permits rapid evaluation of exposure levels to
chemicals with little or no chemical-speciﬁc toxicology data
to determine if exposures are suﬃcient to trigger concern
for a potential for health risk. Exposures below the TTCs are
judged to pose a very low probability of an appreciable risk
to human health.
Although the approach was originally developed to sup-
port exposures to indirect food additives and later to dietary
exposures, the underlying datasets are broad and, conse-
quently, application of the TTC concept to a broader range
of exposure scenarios has been considered [32–37]. Initial
development and application of the TTC approach was6 Journal of Toxicology
focused on systemic exposure resulting from oral adminis-
tration or exposure to compounds. More recently, the TTC
approach was extended to consider systemic exposure fol-
lowing topical application of cosmetic products [32, 35].
There has also been the suggestion that TTC can be applied
to inhalation exposure and risk assessment [33, 35–37]. It
also has been proposed that the TTC can be applied to
intentionally added materials found at low concentrations in
food [7, 34]. Although there are broad categories of chem-
icals that can be evaluated using the TTC, there are certain
materialsthathaveinsuﬃcientdataintheunderlyingtoxicity
datasets, have been identiﬁed as carcinogens with potencies
that fall outside of the distribution, or have concerns related
to bioaccumulation for the TTC to be applied. These include
metals, organometals, and the polyhalogenated dioxins,
furans and biphenyl derivatives [27].
Application of the TTC requires a careful evaluation of
the chemical(s) under consideration and application of the
decision tree to assign the chemical to the appropriate tier
of the decision tree. This decision tree is outlined in several
publications [27] and has been implemented as part of the
OECD QSAR Toolbox (available at http://www.oecd.org/
document/54/0,3746,en 2649 34379 42923638 1 1 1 1,00
.html). An additional module is also available for identifying
alerts for carcinogenicity that may be used as part of the
weight of the evidence on whether or not to consider the
chemical as a potential genotoxic carcinogen. Use of the de-
cisiontreeapproachoﬀersawaytoprioritizewhichmaterials
need more in-depth evaluation.
The TTC methodology was developed to evaluate the
potential for risk to low-level exposure to chemicals in the
diet and has subsequently been applied to ingredients or
contaminants in pharmaceutical and consumer products.
Since biomonitoring represents a “real-world” measurement
of such low-level exposure application of the TTC principles
oﬀers an approach to evaluating the measured exposures in
a risk-based context. TTC values are typically expressed as
applied doses, as either mg/kg-day or mg/day (for a deﬁned
population).TouseaTTCvaluetointerprethumanbiomon-
itoring data thus requires conversion to an internal dose
concentration. If suﬃcient chemical-speciﬁc toxicokinetic
data are available, the TTC could be translated into a corre-
sponding biomarker concentration under the assumption of
chronic steady-state exposure at the TTC level. As discussed
above,inconvertingtoaninternaldoseconcentration,atten-
tion must be paid to proper application of AFs for dynamics
and kinetics to avoid “double counting.” This typically will
entail review of the derivation of TTC, removal of the default
AF used for toxicokinetics, then applying chemical-speciﬁc
toxicokinetic data or models to obtain an internal biomarker
concentration level equivalent to the TTC. Biomonitoring
results can then be interpreted in a risk context using the
MOS procedure. This would also provide a way to identify
chemicals where additional biomonitoring would add little
value. For example, if a chemical was in Cramer Class 3,
which has an assigned TTC of 90µg/day, and the biomoni-
toring data such as those from national biomonitoring pro-
grams such as the US National Health and Nutrition Exami-
nation Survey (NHANES) or the Canadian Health Measures
Survey (CHMS) indicated, through reverse dosimetry esti-
mations,thatexposurelevelsatthe95thpercentilewerelikely
orders of magnitude less than 90µg/day, that chemical could
beacandidateforremovalfromthebiomonitoringprogram.
In a practical sense, for a chemical with little or no
toxicological data for which the TTC approach is used
to identify a screening intake level, the chemical-speciﬁc
toxicokinetic dataormeasurementsrequiredtoestimatecor-
responding biomarker values may not be available. In such
cases, generic toxicokinetic approaches may be considered;
these are discussed further below.
2.4. Risk-Based Interpretation of Biomonitoring in the Absence
of Chemical-Speciﬁc Toxicokinetic Data or Models. For many
chemicals, risk assessment-based exposure guidance values
or robust POD values are available. However, little or no
chemical-speciﬁc toxicokinetic data may exist because such
data have not necessarily been considered to be part of the
core toxicological test batteries used to assess chemical safety.
For such chemicals, provisional estimates of biomarker
concentrations corresponding to key benchmarks may still
be possible, albeit with greater uncertainty or built-in con-
servatism.
One approach relies upon a read-across from other
chemicals that are structurally similar or that have similar
chemical and physical properties. If chemicals are closely
related, data for a well-studied chemical may be used and
serve as a surrogate for a structurally similar compound
with fewer data. Recently criteria have been established for
structural analog identiﬁcation and selection [38], and this
process has been validated with a set of case studies [39].
More broadly, chemicals that exhibit similar physical and
chemical properties may be evaluated using a generic model
applicable to that class. For example, Chiu and White [40]
demonstrated the derivation and application of steady-state
solutions to a generic physiologically based toxicokinetic
(PBTK) model for volatile organic compounds (VOCs)
in route-to-route extrapolation. The steady-state solutions
require very limited chemical-speciﬁc data to implement,
and such data can often be generated in vitro [41]. Aylward
et al. [42] collected the required chemical-speciﬁc data from
the literature as well as current risk assessment-based expo-
sure guidance values for approximately 40 VOC compounds.
They implemented the steady-state solutions to the generic
PBTK model to estimate steady-state blood concentrations
predicted to arise from steady-state exposures.
The resulting estimated chemical-speciﬁc blood concen-
trations corresponding to exposure guidance values were
proposed for use as screening values for evaluation of bio-
monitoring data for these VOCs [42]. Across this class of
compounds, variation in physical/chemical and metabolic
properties resulted in estimated steady-state blood concen-
trations for a unit inhalation exposure (e.g., 1mg/m3) that
varied by approximately one order of magnitude, while those
arising from a unit of oral exposure (1mg/kg-day) varied
over approximately 2 orders of magnitude [42]. Therefore,
if an exposure guidance value is available for a chemical
expected to have similar physical, chemical, and metabolicJournal of Toxicology 7
behavior to those included here, a range of likely steady-
state blood concentrations potentially consistent with the
exposure guidance value could be estimated.
Other PBTK model structures potentially applicable to
a wider range of compounds have been proposed and used
in a variety of contexts. Rotroﬀ et al. [43]u s e di nv i t r o
methods to develop estimates of the metabolic clearance and
protein binding for a series of chemicals included in the
US EPA Phase I ToxCast program. These parameters were
used in a generic PBTK model to relate blood or serum
concentrations to corresponding steady-state external dose
ratesusingcommerciallyavailablesoftware.Bartelsetal.[44]
presented initial results of a comprehensive eﬀort to develop
a generic PBTK model structure that accommodates varying
levels of chemical-speciﬁc information and allows prediction
of biomarker concentrations (both urinary and blood)
associated with a speciﬁed exposure guidance value. On the
toxicity assessment front, Louisse et al. [45] demonstrated
the integration of in vitro toxicity data with toxicokinetic
models to assess glycol ethers. These eﬀorts highlight the
potential utility of targeted data development including in
vitro assessments of metabolism and measured or estimated
chemical and physical properties in allowing development of
provisional biomarker screening or assessment values based
on current risk assessments. If human biomonitoring data
approach or exceed these screening values, allocation of
resources to development of more detailed, data-driven eval-
uations of toxicokinetic characteristics may be appropriate.
2.5. Risk-Based Interpretation of Biomonitoring in the Absence
of Both Guidance Values and Toxicokinetic Data. Most of
the chemicals currently being assessed in the US NHANES
and the Canadian Health Measures Surveys are well-studied
substances. However, even among this group of compounds,
there is sometimes a lack of derived toxicity guidance values,
and, more commonly, a lack of detailed chemical-speciﬁc
toxicokinetic data needed to translate external exposure lev-
els into expected corresponding biomarker concentrations as
required to support development of BEs. As biomonitoring
programs are expanded to include less well-studied sub-
stances, compounds that lack both comprehensive toxicity
datasets, and toxicokinetic data needed for development
of full BE values are likely to be included. In such cases,
provisional screening assessment values may still be derived
using combinations of the approaches outlined above.
For example, the Aylward et al. [42]e v a l u a t i o no fs c r e e n -
ing BE values for assessment of VOCs could be applied
to chemicals lacking both exposure guidance values and
toxicokinetic data. The screening values estimated by Chiu
and White [40] incorporate both the toxicokinetic behavior
ofthechemicalsaswellastheriskassessment-basedtolerable
exposure levels based on noncancer endpoints. The cumula-
tivedistributionofestimatedscreeningbloodconcentrations
for these VOCs is presented in Figure 2. The values span
more than ﬁve orders of magnitude in blood concentration.
If a chemical is judged to be similar in general physical,
chemical, and toxicological characteristics to those included
in the group evaluated by Aylward et al. [42] but lacks the
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Figure 2: Estimated steady-state venous blood concentrations
corresponding to oral and inhalation exposure guidance values (56
values) for 38 VOCs from Aylward et al. [42]. Some chemicals had
bothoralandinhalationexposureguidancevalues,whileothershad
only one.
information necessary for a chemical speciﬁc BE, a lower
percentile of blood concentration from the distribution
represented here might be selected as an initial screening
value for evaluation of blood concentrations of that chemical
measured in humans. This approach is conceptually similar
to the TTC approach, but conducted on a biomarker
concentration basis rather than an intake dose basis.
Similarly, the TTC approach could be applied to a
chemical to estimate a conservative level of tolerable external
exposure, and a generic PBTK model such as that developed
by Bartels et al. [44] could be used to estimate a correspond-
ing biomarker concentration for use as a screening value.
2.6. Decision Tree for Screening Level, Risk-Based Interpre-
tation of Biomonitoring Data. Figure 1 provides a general
ﬂowchart of the various approaches described here. The
ﬂowchart is conceptually similar to the tiered screening
process described in a 2001 review by the Health Council of
the Netherlands [46], with the added component of exten-
sion of the tiered approach to evaluation of biomonitoring
data. These approaches should be applied in an iterative
framework, with increasing reﬁnement indicated when MOS
values are judged to be insuﬃcient. Use of all-generic
approaches to derive provisional screening values clearly
results in values that are highly uncertain, requiring the use
of health-protective assumptions in the screening process. If
chemicals being detected in biomonitoring surveys fall into
this category of lacking both toxicological and toxicokinetic
data, these chemicals may be candidates for early research to
ﬁll selected data gaps in order to reﬁne the assessments for
those chemicals.
3. Discussion and Conclusions
The collection and reporting of human biomonitoring data
continues to grow, and the advanced analytical chemistry8 Journal of Toxicology
techniquesemployedcannowaccuratelyquantifysubstances
in reasonable sample volumes of blood or urine from
individuals. And while authoritative organizations have
cautioned that detection does not equate to illness or injury,
the absence of methods to interpret human biomonitoring
in a health risk context reduces the value of these data
because of the inability to prioritize among the detected
chemicals on the basis of potential risk posed by the
detected levels. Employing tools to interpret biomonitoring
data which results in a risk assessment-based context can
assist risk managers in addressing concerns about chemical
exposures. It also provides a framework for determining
whether additional product stewardship and/or regulatory
risk management actions may be warranted.
The BE approach has proven to be useful as a screening
tool to provide an assessment of which chemical biomarkers
are present at levels well below, near, or at or above con-
centrationsthatareconsistentwithexposureguidancevalues
derived in existing authoritative government risk assess-
ments.Asdiscussedhere,theunderlyingapproachdeveloped
for the BEs can also be used in cases where such authoritative
risk assessments are not yet available or where robust toxi-
cokinetic models aren’t at hand. Both the NOAEL approach
and the TTC method discussed here can be used to establish
benchmarks that will allow screening-level evaluation of
biomonitoring data. Although there are uncertainties when
usingsuchmethods,byemployinghealthprotectiveassump-
tions, such as additional uncertainty factors to account for
databaseshortcomings,thederivedPointsofDeparturefrom
the NOAEL and TTC approaches can be used with a reason-
able degree of conﬁdence that they are health protective.
As with any method used for chemical exposure assess-
ment, the quality and representativeness of the biomonitor-
ing data must be considered in the process of interpreting
the data. While a complete discussion of the factors relevant
to evaluation of biomonitoring data is outside the scope of
this paper, some of these factors include the stability and
speciﬁcity of the biomarker and the representativeness of
the sampling frame used to generate the data. Similarly, the
robustness and reliability of the toxicokinetic models and
data used to translate aﬀect the conﬁdence in the derived
Biomonitoring Equivalents (discussed in Hays et al. [9]).
The methods described here represent a range of ap-
proaches that can be applied depending on the level of
chemical-speciﬁc information available. Obviously, as the
level of chemical-speciﬁc data decreases and reliance on
generic assumptions increases, the uncertainty associated
with the derived screening values increases. If human biom-
onitoring data approach or exceed these screening values,
allocation of resources to development of more detailed,
data-driven evaluations may be appropriate in order to
inform risk managers. In such cases, an iterative approach
to development and application of human biomonitoring
assessment values is appropriate. Such an approach allows
for and takes advantage of targeted data development.
Such data may include in vitro assessments of metabolism,
measured or estimated chemical and physical properties,
or in vivo toxicokinetics and metabolism studies to reﬁne
provisional toxicokinetic estimates.
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